Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Shares Outstanding (2018 - 2025)

Historic Shares Outstanding for X4 Pharmaceuticals (XFOR) over the last 8 years, with Q3 2025 value amounting to $25.1 million.

  • X4 Pharmaceuticals' Shares Outstanding rose 34768.07% to $25.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.1 million, marking a year-over-year increase of 34768.07%. This contributed to the annual value of $5.7 million for FY2024, which is 209.77% up from last year.
  • According to the latest figures from Q3 2025, X4 Pharmaceuticals' Shares Outstanding is $25.1 million, which was up 34768.07% from $8.0 million recorded in Q2 2025.
  • In the past 5 years, X4 Pharmaceuticals' Shares Outstanding ranged from a high of $164.7 million in Q3 2023 and a low of $5.6 million during Q4 2023
  • For the 5-year period, X4 Pharmaceuticals' Shares Outstanding averaged around $45.9 million, with its median value being $24.7 million (2021).
  • In the last 5 years, X4 Pharmaceuticals' Shares Outstanding skyrocketed by 43053.13% in 2023 and then plummeted by 9659.01% in 2024.
  • X4 Pharmaceuticals' Shares Outstanding (Quarter) stood at $28.1 million in 2021, then surged by 332.55% to $121.7 million in 2022, then plummeted by 95.41% to $5.6 million in 2023, then increased by 2.1% to $5.7 million in 2024, then surged by 341.3% to $25.1 million in 2025.
  • Its Shares Outstanding was $25.1 million in Q3 2025, compared to $8.0 million in Q2 2025 and $5.8 million in Q1 2025.